Search results
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 17 hours agoCancer vaccines are finally showing promise as Moderna and Merck touted promising data on an...
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 1 day agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 1 day agoAs Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on...
Study shows new cancer vaccine to treat melanoma has 96% survival rate
UNILAD· 5 hours agoA new vaccine treatment for skin cancer melanoma has shown extremely promising results in a new...
A shot in the arm that can help fight cancer? How vaccine trials are showing promise.
USA TODAY via Yahoo News· 6 hours agoThe new data in patients with advanced melanoma, a type of skin cancer, shows that three years after...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 1 day agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Reuters· 1 day ago, opens new tab said on Monday their cancer vaccine in combination with blockbuster cancer therapy...
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga· 2 hours agoOn Monday, Moderna MRNA and Merck & Co MRK also reported durable efficiency of their combined...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 1 day agoMelanoma patients who received monthly mRNA vaccines and Merck’s Keytruda immunotherapy had lower...
Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate By...
Investing.com· 1 day agoModerna (NASDAQ:MRNA) and Merck (MRK) have released new, more encouraging three-year data on their...